Puma Biotechnology, Inc. beat EPS estimates 81% of the time across 16 reported quarters (13 beats, 3 misses), averaging +25.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $0.16 | not reported | not reported | Q2 FY26 call |
| Q1 FY26 | $-0.17 | $-0.07 | +58.8% | Beat | |
| Q4 FY25 | $0.19 | $0.26 | +36.8% | Beat | |
| Q3 FY25 | $0.07 | $0.17 | +142.9% | Beat | |
| Q2 FY25 | $0.08 | $0.12 | +50.0% | Beat | |
| Q1 FY25 | not reported | $0.06 | not reported | not reported | |
| Q4 FY24 | not reported | $0.39 | not reported | not reported | |
| Q3 FY24 | $0.31 | $0.41 | +32.3% | Beat | |
| Q2 FY24 | $-0.14 | $-0.09 | +35.7% | Beat | |
| Q1 FY24 | $-0.22 | $-0.10 | +54.5% | Beat | |
| Q4 FY23 | $0.33 | $0.26 | -21.2% | Miss | |
| Q3 FY23 | $0.08 | $0.12 | +50.0% | Beat |
Back to PBYI overview · PBYI holders · PBYI KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.